
Martinelli's recalls 170,000 apple juice bottles over toxic mold risk
The Watsonville (Santa Cruz County) juice company initiated the recall in March. The Food and Drug Administration classified it as a Class II recall last week, affecting 7,234 cases of 10-ounce glass bottles sold in 4-packs, each with a white metal screw-top lid.
The bottles in question were produced in December 2023 and have a best by date of Dec. 5, 2026. They are marked with UPC number 0 41244 04102 2.
No illnesses have been reported, and the company said all affected products have been removed from store shelves in 28 states, including California.
According to the FDA, patulin is a naturally occurring toxin that may cause nausea, vomiting and gastrointestinal issues. The Class II classification means the product could lead to temporary or medically reversible health effects, though the likelihood of serious harm is low.
'In 2024, the Food & Drug Administration (FDA) routine testing indicated that one lot of 10-ounce Martinelli's Apple Juice glass bottles (in 4-packs only) produced in December 2023 may contain elevated levels of Patulin,' the company said in a statement.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
9 minutes ago
- Yahoo
Wegmans recalls cheese products due to potential listeria contamination
Wegmans is recalling its brand of medium camembert cheese and products that contain it due to potential listeria contamination, which can lead to serious illness. In an alert Wednesday, the U.S. Food and Drug Administration said the affected items, which were sold between July 1 and Aug. 12, include: Wegmans Medium Camembert Soft Ripened Cheese, 8.8 OZ — UPC: 77890-53515 with best by dates of 7/26/25, 8/12/25, and 8/19/ Assorted Cheese Flight, 1 LB — UPC: 2-77100-00000-0. Wegmans Grilling Camembert with Tapenade & Roasted Tomatoes, 10 OZ — UPC: 2-77297-00000-0. Wegmans Caramel Apple Pecan Topped Brie Cheese, 13 OZ — UPC: 2-77645-00000-3. The affected products were sold at Wegmans in the following locations: ConnecticutDelawareMarylandMassachusettsNew JerseyNew YorkNorth CarolinaPennsylvaniaVirginiaWashington, D.C. So far, no illnesses have been reported to Wegmans or its supplier, but officials say customers should not consume the products and can return them for a full refund. Listeria infections are caused by eating food contaminated with the bacteria called Listeria monocytogenes. In healthy individuals, short-term symptoms may include high fever, severe headache, stiffness, nausea, abdominal pain and diarrhea. But for young children, the elderly and those with weakened immune systems, the infection can be serious and sometimes fatal. Listeria infection can also cause miscarriages and stillbirths in pregnant women. President Trump says meeting with Russia's Putin is not to broker peace deal in Ukraine Could Tropical Storm Erin become the first Atlantic hurricane of 2025? Trump claims "land swapping" between Russia, Ukraine will happen Solve the daily Crossword


Newsweek
12 minutes ago
- Newsweek
Gen Z and Millennials Have Differing Views on Ozempic
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. Gen Z and millennials have radically different views on GLP-1s like Ozempic and how much they want the weight loss and diabetes drugs regulated, according to a new report from GLP-1 prescription weight loss company Levity. While 40 percent of current and recent GLP-1 (glucagon-like peptide-1) users said the current regulations are fair, 28 percent want fewer rules and 22 percent said there should be more. But in the millennial age group, users tend to want less regulation, while Gen Z leaned toward more. Why It Matters GLP-1s, which are injectable drugs that mimic hormones to reduce blood sugar and promote weight loss, have skyrocketed in popularity in recent years. Popular products, including Ozempic, Mounjaro, Wegovy and Zephound, have been a game changer for many Americans who are obese or have type 2 diabetes. However, stricter FDA rules are now in effect, banning certain compounded GLP-1s and making it more difficult for many Americans to secure the drugs, especially if using it for weight loss reasons. Ozempic is medicine for adults with type 2 diabetes. Ozempic is medicine for adults with type 2 diabetes. Steve Christo - Corbis/Corbis via Getty Images What To Know The Gen Z and millennial response to the stricter FDA rules have been notably different, according to Levity. At 31 percent, millennials were the most likely to favor fewer GLP-1 regulations compared to 19 percent of the group who wanted more. Gen Z, meanwhile, favored stricter rules at 37 percent, while 32 percent wanted fewer. "Millennials are more likely to be prescribed a GLP-1 as compared to Gen Z; therefore, it is not surprising that millennials desire less regulation on these drugs," Richard Frank, MD, MHSA, and chief medical officer at Vida Health, told Newsweek. "Having said that, the regulatory environment surrounding compounded agents, in general, and compounded GLP-1s, specifically, is not as rigorous as it is for branded and generic drugs. Therefore, compounded drugs carry unknown risks that more regulated medications do not." Because semaglutide is no longer on the FDA shortage list, compounding it can carry legal risks. Already, the effects are being felt, as 17 percent of GLP-1 users said it has become harder to get their medication since the FDA tightened rules on compounded semaglutide, Levity reported. There was also a difference in how the generations viewed their use of the drugs. While 75 percent of GLP-1 users believed they'll still be on their treatment plan a year from now, Gen Z was the least likely to think so, at 58 percent. What People Are Saying Board-certified endocrinologist Dr. Caroline Messer told Newsweek: "Millennials, many of whom are now managing midlife weight and metabolic health concerns, may see GLP-1s as a practical tool and want fewer barriers. Gen Z, meanwhile, is generally more wary of long-term unknowns, hence leaning toward more safeguards. Broadly, Americans are divided but lean toward keeping current regulations." Richard Frank, MD, MHSA, and chief medical officer at Vida Health, told Newsweek: "From a business perspective, limiting access to compounded drugs when branded drugs are available protects the drug companies' patents. This protection provides the financial incentive for drug companies to develop innovative new therapies." What Happens Next The long-term effects of GLP-1 medication use are so far unclear. A recent study discovered a new link between taking GLP-1 drugs and elevated risk of pancreatitis and kidney conditions, including kidney stones. And GLP-1 medications have also been associated with a higher risk of digestive problems, including nausea, vomiting, diarrhea and even stomach paralysis in rare cases.


CBS News
12 minutes ago
- CBS News
Wegmans recalls some cheese products due to potential listeria contamination
Wegmans is recalling its brand of medium camembert cheese and products that contain it due to potential listeria contamination, which can lead to serious illness. In an alert Wednesday, the U.S. Food and Drug Administration said the affected items, which were sold between July 1 and Aug. 12, include: The affected products were sold at Wegmans in the following locations: So far, no illnesses have been reported to Wegmans or its supplier, but officials say customers should not consume the products and can return them for a full refund. Listeria infections are caused by eating food contaminated with the bacteria called Listeria monocytogenes. In healthy individuals, short-term symptoms may include high fever, severe headache, stiffness, nausea, abdominal pain and diarrhea. But for young children, the elderly and those with weakened immune systems, the infection can be serious and sometimes fatal. Listeria infection can also cause miscarriages and stillbirths in pregnant women.